A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy

Oncologist

Volumn 3, Issue 6, 1998, Pages 432-438

  Spector, Jesse I ^a   Lester, Eric P ^b   Chevlen, Eric M ^c   Sciortino, David ^d   Harvey, Jim H ^e   Whaley, William ^f   Madajewicz, Stefan ^g   Isaacs, Randi ^h   Homesley, Howard D ⁱ   Yee, Sharon ^j   Beck, Thomas M ^k   Slmon Tchekmedyian, N ^l   Crawford, Karen H ^m   Ames, Michael ^m   Creed, Mary R ^a,m  

^a Berkshire Hematology Oncology   (United States)

^b LAKELAND REGIONAL MEDICAL CENTER   (United States)

^c ST ELIZABETH HEALTH CENTER   (United States)

^d Fort Wayne Oncology and Hematology Inc   (United States)

^e Sorra Research Center   (United States)

^f West Paces Clinical Research   (United States)

^g STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^h Northern New Jersey Cancer Center   (United States)

ⁱ Carolina Gynecological Oncology   (United States)

^j Mountain States Tumor Institute ^*

^k St Luke's Mountain States Tumor Institute   (United States)

^l Pacific Shores Medical Group   (United States)

^m GLAXOSMITHKLINE   (United States)

more..

Author keywords

Antiemetics; Chemotherapy; Cisplatin; Granisetron; Nausea; Ondansetron; Vomiting

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; GRANISETRON; ONDANSETRON;

ADULT; AGED; APPETITE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0032437872     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-6-432     Document Type: Article

References (19)

1. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
2. Clavel M, Soukop M, Greenstreet YLA. Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 1993;50:180-185.
3. Lindley CM, Hirsch JD, O'Neill CV et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992;1:331-340.
4. 3-Receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173-189.
5. Perez EA, Hesketh PJ, Gandara DR. Serotonin antagonists in the management of cisplatin-induced emesis. Semin Oncol 1991;16:73-80.
6. Aapro MS. Review of experience with ondansetron and granisetron. Ann Oncol 1993;4(suppl 3):9-14.
7. Hainsworth JD. Development of serotonin antagonists for the control of chemotherapy-induced emesis. Semin Surg Oncol 1993;9:279-284.
8. Cubeddu LX, Hoffman IS, Fuenmayor NT et al. Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-816.
9. Navari R, Gandara D, Hesketh S et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-1248.
10. Roila F, Tonato M, Cognetti F. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-678.
11. Chavallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single blind-study. Eur J Cancer 1990;26(suppl 1):33-36.
12. Addelman M, Erlichman C, Fine S et al. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990;8:337-341.
13. Butcher ME. Global experience with ondansetron and future potential. Oncology 1993;50:191-197.
14. Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992;19:26-32.
15. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol 1992;19(suppl 15):20-25.
16. Gralla RJ, Navari RM, Hesketh PJ et al. Single dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based therapy. J Clin Oncol 1998;16:1568-1573.
17. Perez EA, Hesketh P, Sandbach J et al. Comparison of single-dose oral granisetron and intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:754-760.
18. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dosed regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992;10:1969-1975.
19. Carmicheal J, Bessel EM, Hutcheon AW et al. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer 1994;70:1161-1164.